Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression

American Journal of Epidemiology

Volumn 155, Issue 8, 2002, Pages 760-770

  Jacobson, Lisa P ^a   Li, R ^a   Phair, J ^b   Margolick, J B ^a   Rinaldo, C R ^c   Detels, R ^d   Munoz A ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acquired immunodeficiency syndrome; Antiviral agents; Clinical protocols; Cohort studies; Disease progression; HIV protease inhibitors; Reverse transcriptase inhibitors; Treatment outcome

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE PREVALENCE; HEALTH RISK; RISK FACTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RISK ASSESSMENT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ODDS RATIO; RNA, VIRAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 0037090177     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/155.8.760     Document Type: Article

References (41)

1. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
2. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
3. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study
4. Decline in deaths from AIDS due to new antiretrovirals
5. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
6. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
7. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration
8. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
9. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals
10. + T-cell counts in HIV-infected patients
11. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients
12. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: The Swiss HIV Cohort Study
13. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
14. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
15. "Buffalo hump" in men with HIV-1 infection
16. Severe hepatic cytolysis: Incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998
17. Indinavir-associated lipodystrophy
18. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
19. Restoration of the immune system with anti-retroviral therapy
20. Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease
21. + T lymphocytes
22. The Multicenter AIDS Cohort Study: Rationale, organization, and selected characteristics of the participants
23. Factors associated with prevalent human immunodeficiency virus (HIV) infection in the Multicenter AIDS Cohort Study
24. Recent scientific contributions to understanding HIV/AIDS from the Multicenter AIDS Cohort Study
25. The Multicenter AIDS Cohort Study: Retention after 9 1/2 years
26. Quality control in the flow cytometric measurement of T-lymphocyte subsets: The Multicenter AIDS Cohort Study experience
27. Evaluation of a dual-color flow cytometry immunophenotyping panel in a multi-center quality assurance program
28. Effects of anticoagulant, processing delay, and assay method (branched DNA versus reverse transcriptase PCR) on measurement of human immunodeficiency virus type 1 RNA levels in plasma
29. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
30. Changes in survival after acquired immunodeficiency syndrome (AIDS): 1984-1991
31. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis
32. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy
33. Risk of progression to AIDS and death in HIV infected women initiating HAART at different stages of disease
34. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
35. Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus
36. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study
37. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study
38. Models for the incubation of AIDS and variations according to age and period
39. Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection
40. Thymic aging and T-cell regeneration
41. Changes in thymic function with age and during the treatment of HIV infection